NCT06106347

Brief Summary

The digital technology is universal and has spread worldwide; thus, digital behaviour has dramatically changed peoples' lifestyles. Previous studies have reported that individuals interact with digital screens for up to 12 hours daily,1,2 and the American Optometric Association defined a combination of ocular and extraocular symptoms that affects the screen users as computer vision syndrome (CVS).3 However, our current understanding of digital technology and its harmful impact on the eye and public health,1,4,5 visual performance,6-8 sleep patterns,7,8 circadian rhythms,5,8 musculoskeletal system activities,3,4 and underlying physiological mechanisms9 remains incomplete and is associated with misconceptions.1 Therefore, educational programs that include protective measures and health campaigns are necessary.10 Computer vision syndrome (CVS) is also called with other names as digital eye strain (DES),3 occupational asthenopia, digital asthenopia,1 and video display terminal syndrome (VDTS). CVS ocular symptoms include visual blur with an underlying mechanism that is not fully understood,10 dry eye disease (DED),3 eye redness and irritation, eyestrain, fatigue, discomfort, difficulty in refocusing the eyes, and diplopia.3,4. CVS extraocular symptoms include headache, sleep disturbances, depression,7,8 musculoskeletal aches, such as neck/shoulder/back pain, difficulty in writing or holding objects, pain in thumbs, fingers, or wrists because of tendonitis and/or arthritis. Smartphones are used extensively worldwide by people of all ages, and have close-viewing distance, related high-definition resolution, thousands of time-consuming applications and games in stores, and 24/7 Internet connectivity. The decline in visual acuity observed in CVS can be attributed to the screen-induced foveal dysfunction11-13 which is a phenomenon that has been extensively documented in the literature using multifocal electroretinogram (mfERG) examinations. Previous studies11-13 consistently reported the presence of this dysfunction, which has been linked to prolonged exposure to digital screens emitting blue light. Notably, recent research has demonstrated noteworthy improvements in foveal responses following a strict reduction in screen time for duration of four weeks.13 These improvements were found to correspond with enhanced visual performances, indicating a positive relationship between the reversal of screen-induced foveal dysfunction and visual outcomes. These findings highlight the reversible nature of screen-induced foveal dysfunction and its potential impact on visual acuity. They support the notion that reducing screen time can serve as an effective intervention strategy, leading to substantial improvements in both foveal responses and overall visual performance.13 The computer vision syndrome questionnaire (CVS-Q) is a self-administered scale that evaluates the frequency and intensity of 16 ocular and visual symptoms related to the use of digital devices. The scoring of the questionnaire follows the procedure of the original version. The 16 items (CVS-symptoms) are scored with two rating scales: one for frequency (never, occasionally, often, or always), and one for intensity (moderate, intense). The responses to the two rating scales for each item are combined multiplicatively into a single scale called symptom severity, and the result should be recoded as 0 = 0; 1 or 2 = 1; 4 = 2. If the total score is ≥ 6 points, the worker is considered to suffer computer vision syndrome .14 Ocular surface disease index is a quick self-assessment questionnaire of the symptoms of ocular irritation in dry eye disease (DED) and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effect it has on vision-related function in the past week of the patient's life.15 The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.15 DED, also known as keratoconjunctivitis sicca, is the condition of having dry eyes. Symptoms include dryness in the eye, irritation, redness, discharge, blurred vision, and easily fatigued eyes. Symptoms range from mild and occasional to severe and continuous. DED can lead to blurred vision, instability of the tear film, increased risk of damage to the ocular surface such as scaring of the cornea, and changes in the eye including the neurosensory system.16

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2023

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

October 24, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 30, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2024

Completed
Last Updated

October 30, 2023

Status Verified

October 1, 2023

Enrollment Period

1 year

First QC Date

October 24, 2023

Last Update Submit

October 24, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • nV/deg2

    physiological macular function

    12 months

Study Arms (2)

CVS group

positive CVS diagnosis

Device: mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)

control

participants with no-CVS diagnosis

Device: mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)

Interventions

physiological macular function

CVS groupcontrol

Eligibility Criteria

Age20 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

include university students and young staff members, 20-30 years old who were spending more than 3 screen-hours daily on average over the last 3 years.

You may qualify if:

  • include university students and young staff members, 20-30 years old who were spending more than 3 screen-hours daily on average over the last 3 years.

You may not qualify if:

  • include amblyopia; strabismus; anisometropia; refractive errors higher than 4 D myopia, 4 D hyperopia, or 4 D astigmatism; difference between subjective and cycloplegic refraction \>1D; and previous or current systemic or eye disease or surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University hospitals

Sohag, Egypt

RECRUITING

Related Publications (4)

  • Vaz FT, Henriques SP, Silva DS, Roque J, Lopes AS, Mota M. Digital Asthenopia: Portuguese Group of Ergophthalmology Survey. Acta Med Port. 2019 Apr 30;32(4):260-265. doi: 10.20344/amp.10942. Epub 2019 Apr 30.

    PMID: 31067419BACKGROUND
  • Ahmed SF, McDermott KC, Burge WK, Ahmed IIK, Varma DK, Liao YJ, Crandall AS, Khaderi SKR. Visual function, digital behavior and the vision performance index. Clin Ophthalmol. 2018 Dec 10;12:2553-2561. doi: 10.2147/OPTH.S187131. eCollection 2018.

    PMID: 30573945BACKGROUND
  • Iqbal M, Said O, Ibrahim O, Soliman A. Visual Sequelae of Computer Vision Syndrome: A Cross-Sectional Case-Control Study. J Ophthalmol. 2021 Apr 2;2021:6630286. doi: 10.1155/2021/6630286. eCollection 2021.

    PMID: 33868724BACKGROUND
  • Iqbal M, Soliman A, Ibrahim O, Gad A. Analysis of the Outcomes of the Screen-Time Reduction in Computer Vision Syndrome: A Cohort Comparative Study. Clin Ophthalmol. 2023 Jan 7;17:123-134. doi: 10.2147/OPTH.S399044. eCollection 2023.

    PMID: 36644605BACKGROUND

Central Study Contacts

Mostafa R Refaee, Resident

CONTACT

Mohammed I Hafaz, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident of ophthalmology department, Sohag University Hospitals

Study Record Dates

First Submitted

October 24, 2023

First Posted

October 30, 2023

Study Start

October 15, 2023

Primary Completion

October 15, 2024

Study Completion

October 15, 2024

Last Updated

October 30, 2023

Record last verified: 2023-10

Locations